Ozempic India
- All
- News
- Videos
- Web Stories
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
Using Weight-Loss Drugs May Up Your Risk Of Fractures And Gout By 30%, Says New Study
A new study presented at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting suggests that weight-loss drugs may increase the risk of fractures and gout. Here is what you should know about this revelation and how to be careful.
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
Weight-Loss Surgery May Protect Your Heart More Than Drugs Like Ozempic, Mounjaro: Study
A new study suggests bariatric surgery may offer stronger long-term heart protection than GLP-1 drugs like Ozempic and Mounjaro.
-
People Continue Taking Ozempic For Weight Loss Despite Side Effects, Reveals Study
The study found that the perceived effectiveness of Ozempic for weight loss is the primary driver of patient satisfaction and intent to continue treatment, even when experiencing side effects.
-
Just Taking Ozempic Won't Help With Weight Loss, Daily Exercise Still Matters: New Study Warns
A new randomized trial shows that GLP-1 weight-loss drugs like liraglutide help reduce weight but don't improve physical fitness on their own. Structured exercise is essential for meaningful improvements in cardiorespiratory fitness, mobility, and lo
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
-
India Cracks Down On Ads For Weight-Loss Drugs Like GLP-1 In New Advisory
India's Health Ministry has warned pharmaceutical firms against promoting GLP-1 weight-loss drugs to the public. The CDSCO says direct or indirect advertising, including influencer campaigns, violates drug laws and could attract regulatory action.
-
Using Weight-Loss Drugs May Up Your Risk Of Fractures And Gout By 30%, Says New Study
A new study presented at the American Academy of Orthopaedic Surgeons (AAOS) 2026 Annual Meeting suggests that weight-loss drugs may increase the risk of fractures and gout. Here is what you should know about this revelation and how to be careful.
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report
As the patent for semaglutide, the active ingredient in Ozempic, nears expiry, Indian pharmaceutical companies are preparing to launch cheaper generic versions.
-
Weight-Loss Surgery May Protect Your Heart More Than Drugs Like Ozempic, Mounjaro: Study
A new study suggests bariatric surgery may offer stronger long-term heart protection than GLP-1 drugs like Ozempic and Mounjaro.
-
People Continue Taking Ozempic For Weight Loss Despite Side Effects, Reveals Study
The study found that the perceived effectiveness of Ozempic for weight loss is the primary driver of patient satisfaction and intent to continue treatment, even when experiencing side effects.
-
Just Taking Ozempic Won't Help With Weight Loss, Daily Exercise Still Matters: New Study Warns
A new randomized trial shows that GLP-1 weight-loss drugs like liraglutide help reduce weight but don't improve physical fitness on their own. Structured exercise is essential for meaningful improvements in cardiorespiratory fitness, mobility, and lo
-
6 In 10 Indians Suffering From Obesity-Related Problems: New Survey Says GLP-1 Drugs To Play Role In Treatment
GLP-1 drugs mimic the GLP-1 hormone in the body, which helps to treat type 2 diabetes and obesity. In India, GLP-1 RAs are available under various names; Ozempic, Wegovy and Mounjaro.
